Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 9

Get the latest international news and world events from around the world.

Log in for authorized contributors

UCLA researchers may be able to treat depression by stimulating the brain itself

Treatment for severe depression can include a combination of medications, therapy sessions and specialized care.

Now, however, UCLA researchers are trying to expand those options. Patients may now be able to stimulate their brain with an implanted device.

Researchers with the Abbott TRANSCEND study designed a device that is surgically implanted in the brain for deep stimulation, a technique that targets specific areas of the brain that are underactivated in people with depression. Several sites around the United States – including UCLA – are evaluating its effectiveness as a treatment for major depressive disorder alongside medication.

Humble Robotics raises $51M for cabless hauler pilots

Humble Robotics raised a $51 million Series A on Thursday to move its cabless, electric Humble Hauler into customer pilots on port drayage and warehouse runs. Obvious Ventures led the round, with participation from existing investors Eclipse and Energy Impact Partners.

The raise brings the San Francisco startup’s total funding to $75 million, about six months after it emerged from stealth with a $24 million seed round and a driverless truck built with no cab. It also funds a bet founder and CEO Eyal Cohen made after a decade on long-haul autonomy: that short, repeatable freight moves, such as port drayage and plant-to-warehouse shuttles, are a more controlled place to put driverless, electric trucks to work than the open highway.

The new money will pay for customer pilots, testing and validation, early manufacturing, and a broader family of vehicles built on Humble’s modular platform, the company said in its release. Humble told FreightWaves Today in September it plans to sell the haulers to third-party operators.

Jenny Kleeman on Sex Robots and Vegan Meat

Six years ago I sat down with investigative journalist Jenny Kleeman to talk about birth, food, sex and death. In other words, the entire human condition.

Back then, parts of our conversation sounded like science fiction. A 3D-printable suicide pod. Lamb fetuses growing in plastic bags. Robots designed to be loved.

Since then, the Sarco pod has been used in Switzerland. Several US states have banned #LabGrownMeat. Millions of people now have #AI companions. And #ArtificialWombs are edging closer to human trials.

Jenny didn’t report on these frontiers from a conference stage. She went and met the people building them. What she found was stranger and more human than any pitch deck promises.

Is a sex robot a cure for loneliness or a business model built on it? Is vegan meat about saving the planet or selling us absolution? And who gets to define a “perfect death”?

I won’t spoil her answers. But one line from our conversation has stayed with me ever since:

Continue reading “Jenny Kleeman on Sex Robots and Vegan Meat” | >

Immunotherapy for Cancer: Current Advances and Future Directions

Immunotherapy delivers a fundamental shift in the treatment of multiple cancers, offering hope for patients with cancer. Unlike conventional therapies, it leverages the patient’s immune system to precisely identify and destroy cancer cells. The remarkable journey of immunotherapy’s has revolutionized oncology and paved the way for the development of modern immunotherapies. Several approaches are applied for immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, tumor microenvironment reprogramming, monoclonal antibodies, cytokine therapies, oncolytic virus therapy and combination strategies. Various immunotherapies are being used for different types of cancers like skin, lung, bladder, kidney, liver, breast and blood cancers. Despite providing an effective cancer treatment, immunotherapies face some challenges in their clinical implementation.

Erratum to “BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma”

Following publication of this article, the authors noticed that the WB bands of c-Myc in Figure 7D were inadvertently misplaced [1]. After carefully checking the original data, the authors confirmed the error occurred during figure assembly. This error does not affect the conclusions of this article. The figure has been corrected in the original HTML and PDF, and Fig. 7D is provided below. The authors would like to apologize for any inconvenience caused.